ANCA ASSOCIATED VASCULITIS
Clinical trials for ANCA ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThis study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
Disease control CompletedThis study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Blood filter showdown: which method clears harmful antibodies faster?
Knowledge-focused CompletedThis study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC